Skip to content

Sinovac initiates pivotal study for its COVID-19 vaccine, in Turkey

September 22, 2020

China based Sinovac Biotech (NASDAQ:SVA) has commenced Phase 3 trials its inactivated COVID-19 vaccine candidate, CoronaVac developed by Sinovac Life Sciences, in Turkey.

The trial will test efficacy and safety of CoronaVac and aims to be a pivotal study to support the licensure of this product.

In recent months, Phase 1/2 trials of CoronaVac in adults and elderly volunteers were conducted in China. The vaccine candidate was well tolerated for different dosage and no serious vaccine-related adverse events were reported.

Both seroconversion rates (generation of antibodies) were above 90%, indicating favorable immunogenicity.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: